Pharmacodynamic Drug-Drug Interactions Considered to be Added in the List of Contraindications with Pharmacological Classification in Korea.
- Author:
Nam Kyung JE
1
;
Dong Sook KIM
;
Grace Juyun KIM
;
Sukhyang LEE
Author Information
1. College of Pharmacy, Pusan National University, Busan 609-735, South Korea.
- Publication Type:Original Article
- Keywords:
drug combinations to avoid;
drug-drug interactions;
pharmacodynamics;
pharmacokinetics
- MeSH:
Alkaloids;
Classification*;
Dopamine;
Drug Interactions;
Drug Utilization Review;
Drug-Related Side Effects and Adverse Reactions;
Humans;
Korea*;
Oxidoreductases;
Pharmacists;
Pharmacokinetics
- From:Korean Journal of Clinical Pharmacy
2015;25(2):120-128
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Drug utilization review program in Korea has provided 'drug combinations to avoid DCA)' alerts to physicians and pharmacists to prevent potential adverse drug events or inappropriate drug use. Seven hundred and six DCA pairs have been announced officially by the Ministry of Food and Drug Safety (MFDS) by March, 2015. Some DCA pairs could be grouped based on the drug interaction mechanism and its consequences. This study aimed to investigate the drug-drug interaction (DDI) pairs, which may be potential DCAs, generated by the drug class-drug class interaction method METHODS: Eleven additive/synergistic and one antagonistic drug class-drug class interaction groups were identified. By combining drugs of two interacting drug class groups, numerous DDI pairs were made. The status and severity of DDI pairs were examined using Lexicomp and Micromedex. Also, the DCA listing rate was calculated. RESULTS: Among 258 DDI pairs generated by the drug class-drug class interaction method, only 142 pairs were identified as official DCA pairs by the MFDS. One hundred and four pairs were identified as potential DCA pairs to be listed. QT prolonging agents-QT prolonging agents, triptans-ergot alkaloids, tricyclic antidepressants-monoamine oxidase inhibitors, and dopamine agonists-dopamine antagonists were identified as drug class-drug class interaction groups which have less than 50 % DCA listing rate. CONCLUSION: To improve the clinicians' adaptability to DCA alerts, the list of DCA pairs needs to be continuously updated.
